MedTrace Logo

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

NCT01725113 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.

Conditions

  • Kidney Failure
  • Secondary Hyperparathyroidism
  • Hyperphosphatemia
  • Hypercalcemia

Interventions

DRUG

Calcitriol

3 times weekly

DRUG

Paricalcitol

3 times weekly

Sponsors & Collaborators

  • Winthrop University Hospital

    lead OTHER

Principal Investigators

  • Shayan Shirazian, MD · Winthrop University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-12-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01725113 on ClinicalTrials.gov